Abstract
The pharmaceutical industry is in need of rapid and accurate methods to screen new drug leads for intestinal permeability potential in the early stages of drug discovery. Excised human jejunal mucosa was used to investigate the permeability of the small intestine to four oral drugs, using a flow-through diffusion system. The four drugs were selected as representative model compounds of drug classes 1 and 3 according to the biopharmaceutics classification system (BCS). The drugs selected were zidovudine, propranolol HCl, didanosine, and enalapril maleate. Permeability values from our in vitro diffusion model were compared with the BCS permeability classification and in vivo and in vitro gastrointestinal drug permeability. The flux rates of the four drugs were influenced by the length of the experiment. Both class 1 drugs showed a significantly higher mean flux rate between 2 and 6 h across the jejunal mucosa compared to the class 3 drugs. The results are therefore in line with the drugs’ BCS classification. The results of this study show that the permeability values of jejunal mucosa obtained with the flow-through diffusion system are good predictors of the selected BCS class 1 and 3 drugs’ permeation, and it concurred with other in vitro and in vivo studies.
Similar content being viewed by others
REFERENCES
P. V. Balimane, S. Chong, and R. A. Morrison. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods. 44:301–312 (2000).
Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, and S. Yamashita. Site of drug absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur. J. Pharm. Sci. 29:240–250 (2006).
M. D. Hamalainen, and A. Frostell-Karlsson. Predicting the intestinal absorption potential of hits and leads. Drug Discov. Today: Technologies. 1:397–405 (2004).
M. Cόrdoba-Diaz, M. Nova, B. Elorza, D. Cόrdoba-Diaz, J.R. Chantres, and M. Cόrdoba-Borrego. Validation protocol of an automated in-line flow-through diffusion equipment for in vitro permeation studies. J. Control. Release. 69:357–367 (2000).
W. Ganong. Review of medical physiology, Appleton&Lange, Stamford, CT, 1995.
H. Lennernas. Animal data: The contributions of the Ussing Chamber and perfusion systems to predict human oral drug delivery in vivo. Adv. Drug Deliv. Rev. 59:1103–1120 (2007).
WHO website. http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf (accessed on 19/08/2008)
P. Van der Bijl, A. D. Van Eyk, H. I. Seifart, F. De Jager, and C. M. M. Nel. Diffusion of diclofenac and piroxicam from commercially available gels through human skin. South African J. Physiother. 59:3–6 (2003).
A. D. Van Eyk, and P. Van der Bijl. Comparative permeability of various chemical markers through human vaginal and buccal mucosa as well as porcine buccal and mouth floor mucosa. Arch. Oral Biol. 49:387–392 (2004).
E. Basson, P. Van der Bijl, and A. D. Van Eyk. Transvaginal diffusion of synthetic peptides. Eur. J. Inflamm. 5:15–20 (2007).
H. Motulsky. Intuitive Biostatistics, Graphpad Software, New York, Oxford University Press, 1995.
G. Corti, F. Maestrelli, M. Cirri, S. Furlanetto, and P. Mura. Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. Eur. J. Pharm. Sci. 27:346–53 (2006).
C. A. Knupp, W. C. Shyu, R. Dolin, F. T. Valentine, C. McLaren, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:523–535 (1991).
G. L. Drusano, G. J. Yuen, G. Morse, T. P. Cooley, M. Seidlin, J. S. Lambert, H. A. Liebman, F. T. Valentine, and R. Dolin. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob. Agents Chemother. 36:1280–1283 (1992).
S. L. Bramer, J. L. Au, and M. G. Wientjes. Gastrointestinal and hepatic first-pass elimination of 2’,3’-dideoxyinosine in rats. J. Pharmacol. Exp. Ther. 265:731–738 (1993).
P. J. Sinko, J. P. Sutyak, G. D. Leesman, P. Hu, V. D. Makhey, H. Yu, and C. L. Smith. Oral absorption of anti-AIDS nucleoside analogues: 3. Regional absorption and in vivo permeability of 2′,3′-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model. Biopharm. Drug Disp. 18:697–710 (1997).
P. J. Sinko, and P. Hu. Determining intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans. Pharm. Res. 13:108–133 (1996).
L. X. Yu, G. L. Amidon, and J. R. Crison. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140:111–118 (1996).
J. Dressman, and J. Krämer. Pharmaceutical Dissolution Testing, Taylor&Francis Group, Boca Raton, USA, 2005.
Q. Q. Huang, S. Y. Yao, M. W. Ritzel, A. R. Patterson, C. E. Cass, and J. D. Young. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J. Biol. Chem. 269:17757–17760 (1994).
N. Oulianova, D. Cheng, N. Heubert, and Y. Chen. Human oral drugs absorption is correlated to their in vitro uptake by brush border membrane vesicles. Int. J. Pharm. 336:115–121 (2007).
P. J. Sinko, P. Hu, A. P. Waclawski, and N. R. Patel. Oral absorption of anti-AIDS nucleoside analogues. 1 Intestinal transport of didanosine in rat and rabbit preparations. J. Pharm. Sci. 84:959–965 (1995).
G. Trapani, M. Franco, A. Trapani, A. Lopedota, A. Latrofa, E. Gallucci, S. Micelli, and G. Liso. Frog intestinal sac: a new in vitro method for the assessment of intestinal permeability. J. Pharm. Sci. 93:2909–2919 (2004).
S. Yamashita, Y. Tanaka, Y. Endoh, Y. Taki, T. Sakane, T. Nadai, and H. Sezaki. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm. Res. 14:486–491 (1997).
H. Vogelpoel, J. Welink, G. L. Amidon, H. E. Junginger, K. K. Midha, H. Moller, M. Olling, V. P. Shah, and D. M. Barends. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J. Pharm. Sci. 93:1945–1956 (2004).
V. Pade, and S. Stavchansky. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J. Pharm. Sci. 87:1604–1607 (1998).
H. Vogelpel, J. Welink, G. L. Amidon, H. E. Junginger, K. K. Midha, H. Moller, M. Olling, V. P. Shah, and D. M. Barends. Commentary. Biowaiver monographs for immediate release sold oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J. Pharm. Sci. 93:1945–1955 (2004).
D. I. Friedman, and G. L. Amidon. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J. Pharm. Sci. 78:995–998 (1989).
D. I. Friedman, and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 6:1043–1047 (1989).
R. Borchardt. The application of cell culture systems in drug discovery and development editorial. J. Drug Target. 3:179–182 (1995).
W. Rubas, N. Jezyk, and G. M. Grass. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm. Res. 10:113–118 (1993).
P. Artursson, T. Lindmark, S. S. Davis, and L. Illum. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1358–1361 (1994).
F. Li, L. Hong, C.-I. Mau, R. Chan, T. Hendricks, C. Dvorak, C. Yee, J. Harris, and T. Alfredson. Transport of levovirin prodrugs in the human Intestinal Caco-2 cell line. J. Pharm. Sci. 95:1318–1325 (2006).
H. Lennernäs, S. Nylander, and A.-L. Ungell. Correlation of effective drug permeability measurements in vitro using the Ussing chamber and the human jejunal perfusion. Pharm. Res. 14:667–671 (1997).
D. Sun, H. Lennernäs, L. S. Welage, J. L. Barnett, C. P. Landowski, D. Foster, D. Fleisher, K. D. Lee, and G. L. Amidon. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19:1400–1416 (2002).
H. H. Usansky, and P. J. Sinko. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J. Pharmacol. Exp. Ther. 314:391–399 (2005).
FDA Guidance for Industry. Waiver if in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Food and Drug Administration, Rockville, MD, 2000.
ACKNOWLEDGMENTS
The authors gratefully acknowledge Aspen Pharmacare (South Africa), for providing the four chemicals/drugs. We also thank the surgeons from the Department of Surgical Sciences, Tygerberg for supplying the small intestine specimens.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pretorius, E., Bouic, P.J.D. Permeation of Four Oral Drugs Through Human Intestinal Mucosa. AAPS PharmSciTech 10, 270–275 (2009). https://doi.org/10.1208/s12249-009-9207-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-009-9207-4